期刊文献+

CEA电化学发光免疫分析法的建立 被引量:4

Establishment of Electrochemiluminescence Immunoassay for CEA
下载PDF
导出
摘要 目的建立人癌胚抗原(CEA)的电化学发光免疫分析法(ECLIA)。方法生物素标记的CEA McAb、钌复合物标记配对的CEA McAb、链霉亲和素包被的磁性微粒组成CEA ECLIA试剂,用ECLIA仪检测CEA并做方法学评价。用本法与进口的同类ECLIA试剂对119例结直肠癌、150例肺癌、45例胃癌、32例胰腺癌和34例肝细胞癌患者的血清CEA检测结果进行分析。调查218名志愿者血清CEA正常参考值。结果本法检测CEA的批内CV为1.6%~7.1%,批间CV为2.3%~11.7%,灵敏度为0.2 ng/mL。与CA19-9和AFP无交叉反应。自建ECLIA检测CEA浓度范围为0.2~1000.0ng/mL,正常参考值低于5.6ng/mL。结论自建CEA ECLIA与进口试剂比较(r=0.9641,P<0.05),正常参考范围接近进口同类方法。具备产业化的潜能。 Objective To establish electrochemiluminescence immunoassay(ECLIA) to detect CEA levels in human serum.Methods The CEA monoclonal antibody(McAb) was biotinylated,and the paired CEA McAb was labeled with ruthenium.The microparticles were coated with streptavidin.The CEA levels in 119 patients with intestinal lung cancer,150 lung cancer,45gastro cancer,32 pancreatic cancer,34 primary hepatocellular carcinoma and 218 healthy volunteers were tested by established ECLIA reagent in this study and Roche reagent.Results The results showed that the inter-assay and intra-assay CVs were 1.6 ~7.1% and 2.3~11.7%,respectively.The lower detection limit was 0.2 ng/mL.There was no cross-react with CA199 and AFP.The CEA detection ranges were 0.2 ~1000.0 ng/mL.The detected results with this method were closely corresponded to those of by Roche reagents(r=0.9641,P0.05).Conclusion The established ECLIA for CEA in this study was specific,sensitive and with a good precision.It may have a industrial potentiality.
出处 《标记免疫分析与临床》 CAS 2012年第2期103-106,共4页 Labeled Immunoassays and Clinical Medicine
基金 广州市科技和信息化局基金资助(2010U1-E00681-6)
关键词 癌胚抗原 电化学 发光 免疫分析 电化学发光免疫分析 CEA Electrochemistry Luminescence Immunoassay Electrochemiluminesence immunoassay
  • 相关文献

参考文献8

二级参考文献38

  • 1陈建华,欧阳玉林,朱文彪,彭静.肿瘤标志物癌胚抗原(CEA)检测在非小细胞肺癌诊治中的临床意义[J].现代肿瘤医学,2005,13(2):199-200. 被引量:30
  • 2梁婧,周光英,刘文波,刘海荣.原发性肺癌患者外周血肿瘤标记物联合检测的临床意义[J].实用癌症杂志,2005,20(2):154-157. 被引量:5
  • 3Rφder ME, Dinesen B, Harding SG, et al. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care, 1999,22:609-614.
  • 4Snehalatha C, Ramachandran A, Saltyamurthy I, et al. Association of proinsulin and insulin resistance with coronary artey disease in non-diabetic south Indian men. Diabet Med, 2001,18: 706-708.
  • 5National Committee for Clinical Laboratory Standands. Evaluation of p recision performance of clinical chemistry devices. EP52A. Wayne, PA: NCCLS, 1999.
  • 6Jhang JS, Chang CC, Fink DJ. Evaluation of linearity in the clinical laboratory. Arch Pathol Lab Med, 2004,128:44.
  • 7Pfutzner A, Kunt T, Langenfeld M, et al. Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin. Clin Chem Lab Med, 2003,41:1234-1238.
  • 8Zethelius B, Byberg L, Hales CN, et al. Proinsulin and acute insulin response independently predict Type 2 diabetes mellitus in men-Report from 27 years of follow-up study. Diabetologia, 2003, 46 : 20 -26.
  • 9Pfutzner A, Standl E, Hohberg C, et al. IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design. Diabetes Techuol Ther, 2005,7:478-486.
  • 10Rougier P, Mitry E. Epidemiology, treatment and chemoprevention in colorectal cancer[J].Annals of Oncology, 2003,14(Suppl 2) :3-5.

共引文献51

同被引文献44

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部